For Healthcare Professionals

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

clipboard-pencil

About the study

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Are active SCLE, DLE and/or SLE that have completed the 24 week Treatment of the Willow Study
  2. Have a Body Mass Index (BMI) within the >= 40 kilograms per meter square (inclusive) at Screening
  3. Other protocol defined inclusion criteria could apply

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Participants who experienced serious event(s) related to the study intervention during the WILLOW study
  2. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Long Term Extension (LTE) study participation
  3. Ongoing or active clinically significant viral (including Severe acute respiratory syndrome coronavirus 2 [(SARS-CoV-2)], bacterial or fungal infection, or any major episode of infection requiring hospitalization
  4. Received LTE prohibited medication during the WILLOW study or after the WILLOW study Week 24
  5. Participation in any other investigational drug study after the WILLOW study Week 24
  6. Other protocol defined exclusion criteria could apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +49 6151 72 5200Email iconEmail Study Center

Study’s details


Contition

Systemic Lupus Erythematosus

Age (in years)

18 - 76

Phase

Phase 2

Participants needed

532

Est. Completion Date

Apr 15, 2025

Treatment type

Interventional


Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

ClinicalTrials.gov identifier

NCT05540327

Study number

MS200569_0048

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.